AMZN
Amazon.com, Inc.
AMZN has the edge over CCK overall, supported by stronger modeled upside and stronger valuation.
CCK
Crown Holdings, Inc.
CCK's outlook is improving, though it still trails on the overall score.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
CCK Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Stable |
CCK's revenue and profitability are currently healthy, and its cash flow and balance sheet are stable.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN has the edge over CCK in the historical PE scenario, which offers more potential upside but is not a forecast.
CCK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 14x | $120 | — |
| Cheap | 16x | $118 | -2.4% |
| Current | 17x | $120 | — |
| Fair | 21x | $149 | +24% |
| Expensive | 25x | $178 | +48% |
Historical ranges are pointers, not guarantees.
CCK's PE is in its cheap range at 17x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AMZN, with profitability improving.
CCK Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for CCK, with profitability holding steady.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over CCK on earnings, with more consistent year-over-year improvement.
CCK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.74 | +22% |
| Q3 2026 | $7.19 | -11% |
| Q2 2026 | $6.96 | +47% |
| Q1 2026 | $6.29 | +36% |
| Q4 2025 | $6.38 | +80% |
| Q3 2025 | $8.07 | +896% |
| Q2 2025 | $4.75 | +32% |
| Q1 2025 | $4.64 | +34% |
| Q4 2024 | $3.55 | -5.6% |
CCK earned $7.19 per share over the past year, down 11% from the year before.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over CCK on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over CCK on profitability, with a higher operating margin.
CCK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +16% |
| Q2 2026 | $3.7B | +16% |
| Q1 2026 | $3.3B | +13% |
| Q4 2025 | $3.1B | +7.7% |
| Q3 2025 | $3.2B | +4.2% |
| Q2 2025 | $3.1B | +3.6% |
| Q1 2025 | $2.9B | +3.7% |
| Q4 2024 | $2.9B | +1.6% |
CCK's revenue has grown year over year for nine quarters in a row: $3.7B last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | -1.3 points |
| Q2 2026 | 13% | +0.2 points |
| Q1 2026 | 11% | -1.4 points |
| Q4 2025 | 12% | -0.1 points |
| Q3 2025 | 13% | -1.2 points |
| Q2 2025 | 12% | -0.1 points |
| Q1 2025 | 13% | +3.8 points |
| Q4 2024 | 12% | +3 points |
CCK's operating margin was 12% last quarter, down 1.3 points from the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
CCK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $299M | -39% |
| Q2 2026 | $597M | +52% |
| Q1 2026 | -$141M | -$122M |
| Q4 2025 | $255M | +75% |
| Q3 2025 | $488M | +2.1% |
| Q2 2025 | $393M | +8.9% |
| Q1 2025 | -$19M | +$177M |
| Q4 2024 | $146M | -67% |
CCK has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
CCK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.4% | -1.5M shares |
| 1 year | -6.4% | -7.4M shares |
| 3 years | -9.5% | -11.4M shares |
| 5 years | -16% | -21.4M shares |
| Available history | -20% | -26.9M shares |
CCK has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $81M |
| Q2 2026 | $305M |
| Q1 2026 | $212M |
| Q4 2025 | $191M |
| Q3 2025 | $105M |
| Q2 2025 | $6M |
| Q1 2025 | $203M |
| Q4 2024 | $100M |
CCK spent $789M buying back its own shares over the past year, up 91% from the year before.
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN has the edge over CCK on leverage, with a lower net debt burden relative to earnings.
CCK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.5x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.8x | Moderate |
| Q4 2025 | 2.6x | Moderate |
CCK's net debt is about 2.5 years of its operating earnings (EBITDA).
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
CCK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.6 | Neutral |
| Stochastic | 77.9 | Neutral |
CCK's weekly RSI is 63 (neutral) and its Stochastic is 78 (neutral).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
CCK PE vs Consumer Cyclical Sector
| Metric | CCK | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 18x | 7% below |
| PE % | 19 | 47 | 28 pts below |
CCK has the edge over AMZN on valuation relative to its sector.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN is in an uptrend: it's above all five of its weekly moving averages, and 40% above its 200-week average.
CCK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $114.4 | 5.4% above |
| 20 week MA | $115.4 | 4.4% above |
| 50 week MA | $108.1 | 11% above |
| 100 week MA | $101.1 | 19% above |
| 200 week MA | $93.1 | 29% above |
CCK is in an uptrend: it's above all five of its weekly moving averages, and 29% above its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has finished higher in five of the last six years, two of them by more than 50%. It's up 15% so far in 2026.
CCK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $73.2 | $98.6 | +35% |
| 2021 | $98.6 | $105.7 | +7.2% |
| 2022 | $105.7 | $82.6 | -22% |
| 2023 | $82.6 | $92.1 | +12% |
| 2024 | $92.1 | $83.2 | -9.7% |
| 2025 | $83.2 | $102.9 | +24% |
| 2026 YTD | $102.9 | $120.5 | +17% |
CCK has the edge over AMZN on returns for 2026, with the stronger performance.